Curidol

Quick links to important sections

Curidol

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Curidol

Property Description
Active ingredients Acetaminophen, Tramadol Hydrochloride
Form Oral tablets
Pharmacological class Narcotic Analgesic Combination
Common use Pain Management (Moderate to Moderately Severe)
Origin Synthetic

What Type of Medicine is Curidol?

Curidol is a synthetic, fixed-dose combination analgesic administered as oral tablets. This medicine is classified as a narcotic analgesic combination because its formula includes Tramadol Hydrochloride, an opioid component. This classification mandates that Curidol is a prescription-only drug (Rx).

The combination of these two compounds—a non-opioid analgesic and an atypical opioid—is typically intended for patients whose moderate to moderately severe pain requires a treatment solution that goes beyond single-agent therapies. Other recognized fixed-dose products utilize this identical active ingredient combination, demonstrating the therapeutic concept.


What are the Active Ingredients in Curidol Tablets?

The composition of Curidol features two principal active ingredients: Acetaminophen (known as Paracetamol) and Tramadol Hydrochloride. Acetaminophen contributes a peripheral pain-relief mechanism, while Tramadol is a centrally acting analgesic.

The combination’s design offers a distinct advantage over single-ingredient pain relievers, a concept widely recognized in clinical guidelines. Tramadol works as a weak agonist at the mu-opioid receptor and also inhibits the neuronal reuptake of norepinephrine and serotonin. This multi-target engagement is key to the drug's effectiveness.


What is the General Purpose of Combining Acetaminophen and Tramadol?

The overarching purpose of Curidol is to provide effective pain management, such as for acute injuries or post-operative discomfort that is rated as moderate to moderately severe. The deliberate integration of both non-opioid and atypical opioid actions is intended to create a synergistic analgesic effect by addressing pain signals at multiple points.

By targeting both peripheral chemical mediators and central pain perception centers, this design ensures that the drug engages different mechanisms simultaneously. This strategy provides a robust method for managing pain when a simpler, single-action drug is insufficient, making it a valuable tool in structured pain relief protocols.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Curidol?

Possible Side Effects and Safety Information

The safety profile of Curidol (Acetaminophen and Tramadol combination) is documented by regulatory authorities, classifying potential outcomes by frequency and affected organ system. The most Very Common adverse reactions reported (affecting more than 1 in 10 individuals) are nausea, dizziness, and somnolence (drowsiness), affecting the gastrointestinal and nervous systems. Common effects include constipation, dry mouth, headache, vomiting, and sweating.


Serious Safety Considerations

Official labeling mandates specific warnings for several serious risks. Due to the Acetaminophen component, exceeding the maximum daily dose carries a high risk of severe hepatotoxicity (liver damage). The opioid component, Tramadol, is associated with a risk of drug dependence and abuse, which can lead to life-threatening respiratory depression or withdrawal symptoms that increase with longer duration of use. Other serious risks documented are seizures and Serotonin Syndrome, particularly when the medicine is combined with other serotonergic agents.


Population-Specific Safety Constraints

The medicine is generally not recommended for use in patients with severe hepatic or renal impairment due to compromised drug clearance. Furthermore, it is contraindicated in children younger than 12 years of age and in adolescents under 18 years following tonsillectomy/adenoidectomy. Caution is advised when administering the medicine to older adults (aged 65 years and over), as they may be more sensitive to its effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Curidol contains both an opioid pain reliever and paracetamol (acetaminophen), making overdose a potentially life-threatening medical emergency requiring immediate professional medical attention.

Overdose presents as a combination of two distinct toxicities:

  • Opioid Toxicity: Manifests as severe central nervous system depression, including somnolence, miosis (pinpoint pupils), confusion, and, critically, respiratory depression which can lead to respiratory arrest and death. Convulsions and cardiovascular collapse have also been documented.

  • Paracetamol Toxicity: Initial symptoms may be non-specific, such as nausea, vomiting, and abdominal pain. The primary severe outcome is delayed hepatic necrosis (liver failure), which may not become apparent until 12 to 48 hours after ingestion, potentially progressing to encephalopathy and death.

Required Emergency Actions

Seek emergency medical help immediately if an overdose is known or suspected. Do not wait for symptoms to develop. The official regulatory management strategy requires the rapid administration of two specific antidotes:

  1. Naloxone for the reversal of opioid-induced respiratory depression, though this may increase seizure risk.
  2. N-acetylcysteine (NAC) for the prevention of paracetamol-induced liver damage. NAC must be administered as quickly as possible.

Overdose Risk Factors: Accidental overdose, especially in children, is a specific and potentially fatal risk. Concomitant use with other CNS depressants, including alcohol, or exceeding the maximum recommended daily dose increases the hazard.

Therapeutic Uses of Curidol

Curidol is used in clinical contexts where pain management requires an approach requiring combined action, focusing entirely on providing symptomatic relief and functional comfort. This medication is considered relevant in situations where patients experience acute pain of a severity that typically requires additional support, and for which alternative treatments may be inadequate. Its therapeutic scope includes managing moderate to moderately severe acute discomfort that arises from conditions such as post-operative procedures or acute injuries.


Key Therapeutic Focus

The therapeutic relevance of this medication is to help address symptoms related to high-intensity discomfort and to manage pain that is refractory to typical non-opioid pain management. It is applied across domains where short-term symptom management is appropriate, especially during phases when symptoms become temporarily overwhelming. It supports patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

“It supports patients during difficult episodes by easing distress, especially when acute manifestations create noticeable functional strain.”


Indications and Symptomatic Relief

Curidol is commonly used to help with symptoms that cluster into patterns of pain related to physical discomfort. It is applicable in conditions characterized by periods of heightened symptoms, such as pain after surgery, acute bone or musculoskeletal injury, or episodes of refractory dental discomfort. It provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relevant for Symptomatic Management of Refractory and Moderate-to-Severe Acute Pain

Regulatory References

  1. TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN tablet, film coated - DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Curidol?

This section outlines the official population eligibility and non-eligibility rules for Curidol, based strictly on government regulatory documents (e.g., FDA, EMA SmPC).

Contraindicated Populations

Curidol must not be used by specific patient groups due to regulatory contraindications:

  • Children younger than 12 years of age.
  • Adolescents younger than 18 years of age for pain relief after tonsillectomy or adenoidectomy.
  • Patients with a history of severe hepatic impairment.
  • Patients experiencing significant respiratory depression or acute, severe bronchial asthma.
  • Patients with acute intoxication from alcohol, hypnotics, opioids, or other centrally-acting drugs.
  • Patients who have used Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Special Population Restrictions

Eligibility is restricted for other groups:

  • Pregnancy: Prolonged use is restricted due to the risk of Neonatal Opioid Withdrawal Syndrome.
  • Lactation: Use is not recommended.
  • Severe Renal Impairment (Creatinine clearance below 10 mL/min): Use is not recommended.
  • Adolescents 12 to 18 years with risk factors for respiratory depression (e.g., obesity or lung disease) should avoid use.
  • Geriatric Patients (over 75 years): Use requires careful consideration to prolong the dosing interval.

What should I know about interactions with other medicines?

The official interaction profile for Curidol is defined by several mandatory restrictions documented by regulatory authorities.

Contraindicated Combinations

The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), requiring a mandatory 14-day separation after MAOI discontinuation. Co-administration with any other product containing Tramadol or Acetaminophen is also prohibited to prevent accidental overdose and hepatotoxicity. Use is also contraindicated in acute intoxication with other central nervous system depressants or in patients with severe hepatic impairment.

Pharmacodynamic and Metabolic Interactions

Significant pharmacodynamic interactions result from additive effects with CNS depressants, including alcohol, leading to risks of profound sedation and respiratory depression. Combining Curidol with serotonergic drugs (e.g., SSRIs, triptans) heightens the documented risk of Serotonin Syndrome. Furthermore, co-administration with anticoagulants like warfarin may result in an increase in Prothrombin Time (INR).

The pharmacokinetic profile is sensitive to hepatic enzyme activity. Drugs that inhibit CYP2D6 or CYP3A4 may alter the plasma exposure of Tramadol and its active metabolite (M1). Strong CYP3A4 inducers, notably Carbamazepine, significantly decrease Tramadol concentrations, which is a recognized interaction. Food intake only delays the time to peak concentration (Tmax) of both active ingredients, without affecting the overall extent of absorption.

Mechanism of Action

Curidol engages a synergistic dual mechanism that inhibits nociceptive signal transmission across multiple levels of the central nervous system (CNS). This approach engages both the transmission of nociceptive signals and the underlying molecular processes involved in central pathway sensitization.


Dual Central Inhibition: Opioid and Monoaminergic Pathways

The Tramadol component initiates a central signal blockade by engaging two distinct inhibitory pathways. Its active metabolite ( M1) acts as an agonist at the mu-opioid receptor (mu-MOR), which inhibits the release of nociceptive mediators and hyperpolarizes nociceptive neurons. Simultaneously, the parent drug inhibits the reuptake of both norepinephrine (NE) and serotonin (5-HT), which increases the functional activity of the descending inhibitory pathways. This convergence of opioid and monoaminergic action results in an enhanced suppression of nociceptive signal transmission from the spinal cord to the brain.


Modulation of Central Pathway Sensitization

The Acetaminophen component adds a critical non-opioid layer to the mechanism. It primarily acts as an indirect inhibitor of Cyclooxygenase (COX) enzymes within the CNS, which decreases the synthesis of the nociceptive signaling mediator, Prostaglandin E2 ( PGE2). By limiting PGE2 levels, the mechanism decreases the excitability and sensitization of central nociceptive pathways. This mechanism is complemented by the action of its metabolite (AM404) on the TRPV1 and CB1 receptors, resulting in a cumulative inhibition of afferent nociceptive input.

Dosage and Administration Information

How to Use Curidol — Official Administration Guidelines

Curidol's official usage instructions detail strict adherence to dosing rules for its immediate-release (IR) and extended-release (ER) forms. The medicine is administered via the oral route.


Administration and Dosage

Dosage Form Initial Dosing Maintenance / Maximum Dose
Immediate-Release (IR) Tablets Start at 25 mg once daily, increasing by 25 mg every 3 days to a target of 100 mg/day. The dose may be increased to 50–100 mg every 4 to 6 hours as needed, not to exceed 400 mg/day.
Extended-Release (ER) Forms Start at 100 mg once daily, adjusting by 100 mg every 5 days. Maximum daily dose must not exceed 300 mg/day.

Preparation and Timing:

  • ER Forms must be swallowed whole and must not be chewed, split, or crushed, as this can affect the controlled release of the medicine.
  • IR tablets may be taken with or without food.
  • IR and ER products must not be used together.

Population-Specific and Procedural Rules

Dose Adjustment: Patients with severe kidney impairment (creatinine clearance < 30 mL/min) or severe liver impairment must have their dosing interval extended to 12 hours; the maximum daily dose for IR tablets in this group is restricted to 200 mg.

Geriatric Use: Dosing initiation should be cautious for patients over 65 years, with increased caution for those over 75 years.

Discontinuation: The medicine must not be stopped abruptly in physically dependent patients; a gradual dose taper is required to avoid withdrawal symptoms.

Recent Clinical Evidence

Research evidence / Overview of studies for Curidol


Evidence for Use in Acute Pain Management

Curidol, the combination of acetaminophen and tramadol, was studied in populations with acute pain, which describes sudden, severe discomfort often following an injury or surgical procedure. The main evidence comes from short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time over short treatment periods, typically lasting only a few days, and involved adult patients with moderate to moderately severe pain.

Researchers monitored several key outcomes related to physical discomfort, such as how quickly patients started feeling relief and how much their pain intensity changed, using specialized scoring systems. The findings from these trials describe patterns observed in the studies where the combination was associated with differences in pain scores, including measures of onset and total relief, when compared to placebo or its individual components. The combination product was extensively evaluated in these acute pain settings.


Evidence for Use in Chronic Low Back Pain and Osteoarthritis

Curidol was studied for managing chronic pain, which includes conditions where outcomes reflecting daily functioning or activity level are important. The research for these conditions often involves longer trial durations, extending over weeks to months.

Research examined the combination in adults with chronic low back pain, using intermediate-term RCTs that ranged up to about 12 weeks. Studies reported patterns related to measured differences in pain scores and physical function compared to placebo. Systematic reviews noted that the size of the reported change was described as small in some meta-analyses, and that evidence quality varies across studies.


Evidence in Specific Populations and Research Gaps

Most of the research involving Curidol was studied for use in the general adult population. For instance, the combination was not evaluated in all age groups, and evidence remains limited for children under age 12. For older adults, evidence is often extrapolated from general adult trials.

When evaluating the comprehensive evidence, several key research limitations are identified: Comparative evidence is lacking in large, direct studies that compare Curidol against all other relevant fixed-dose pain relief combinations, and the research provides limited insight into the long-term patterns of use in chronic pain settings. Study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Curidol (FAQ)


Q: Are there any minor side effects of Curidol that patients can generally expect to pass?

A: Official documentation notes that nausea, dizziness, and somnolence (drowsiness) are very common adverse reactions. These effects are frequently reported during the initiation of treatment.


Q: Can Curidol affect a person's sleep patterns, such as causing insomnia or drowsiness?

A: Yes, official safety information lists effects on sleep. Drowsiness (somnolence) is documented as a very common side effect. Insomnia, which is difficulty sleeping, is also listed as a common adverse reaction in official safety information.


Q: Is there any known risk of dependency or withdrawal associated with Curidol?

A: Due to the opioid component in Curidol, official warnings note a risk of drug dependence and abuse. Regulatory documents advise against abrupt cessation; a gradual dose reduction, known as a taper, is described to manage the risk of withdrawal symptoms.


Q: What happens to Curidol in the body after it has been fully absorbed?

A: According to the official product information, Curidol is primarily processed and broken down by the liver. It is then eliminated from the body largely through the kidneys in the form of various processed compounds (metabolites).


Q: What happens if I forget to take my Curidol dose?

A: Patient information generally describes taking the missed dose if sufficient time remains before the next scheduled dose, but skipping it if it is almost time. Official guidance mandates that two doses must never be taken at the same time to prevent overdose.


Q: What are the descriptive guidelines for using Curidol during pregnancy or breastfeeding?

A: Official documents advise that prolonged use during pregnancy is restricted due to the potential risk of Neonatal Opioid Withdrawal Syndrome in newborns. Furthermore, use of Curidol during lactation is generally not recommended by regulatory authorities.


Q: Can individuals with a history of liver or kidney problems use Curidol?

A: The medicine is contraindicated (must not be used) for patients with severe hepatic (liver) impairment. For patients with severe kidney impairment, regulatory documents require a dose adjustment, often involving a longer time interval between doses.


Q: Does Curidol treat the underlying cause or primarily help with symptoms?

A: Curidol is classified as a narcotic analgesic combination, which is a type of medicine primarily used for pain management. The therapeutic function of this medicine is to help relieve physical discomfort or other related symptoms.


Q: How quickly does Curidol typically begin to show an effect after starting treatment?

A: Clinical data and product information indicate that the immediate-release tablet typically begins to show an analgesic effect, meaning relief from pain, within approximately 30 to 60 minutes after it is administered.


Q: Does Curidol cause weight gain, weight loss, or changes in appetite?

A: Official regulatory documentation lists a decrease in appetite, sometimes formally called anorexia, as a common adverse reaction associated with the medicine.


Q: Are there any foods or drinks that must be strictly avoided while on Curidol?

A: Yes, alcohol is strictly warned against by regulatory authorities. The combination of Curidol and alcohol significantly increases the risk of profound sedation, which can lead to life-threatening respiratory depression.


Q: Does Curidol interact with common over-the-counter pain relievers or fever reducers?

A: Regulatory documents explicitly prohibit co-administration (taking at the same time) with any other product containing Acetaminophen or Tramadol. This is a mandatory rule to prevent accidental overdose and the risk of severe liver damage.


Q: Is it safe to drive or operate machinery while undergoing treatment with Curidol?

A: Regulatory warnings state that the medicine may impair the mental and physical abilities needed to perform tasks such as driving or operating heavy machinery, due to risks like dizziness and somnolence.


Q: Does Curidol cause any known changes to vision or eye health?

A: Official adverse reaction lists document that some patients may experience visual disturbances and blurred vision. These are listed as documented, less common effects of the medicine.


Q: Does Curidol accumulate in the body over time?

A: The official pharmacokinetic data, which describes how the drug moves through the body, indicates the time taken for the drug concentrations to reach a steady-state level in the body.


Q: What is the difference in chemical class between Curidol and other common treatments?

A: Curidol is a fixed-dose combination containing two active ingredients. It is composed of Acetaminophen (a non-opioid analgesic) and Tramadol Hydrochloride, which is classified as an atypical opioid.


Q: Why might a person feel dizzy or lightheaded when they first start the treatment?

A: This is documented as a Very Common effect related to the drug’s action on the central nervous system (CNS), often reported upon initiation of treatment.


Q: Is Curidol available in different formulations (e.g., tablet, liquid, extended-release)?

A: The official labeling confirms that the product is available as an oral tablet. It comes in two primary forms: an immediate-release (IR) formulation and an extended-release (ER) formulation.


Q: Does Curidol have any known interaction with dental or surgical anesthesia?

A: Warnings are issued against using the medicine with other central nervous system (CNS depressants), which includes many types of anesthesia. This combination carries an increased risk of severe sedation and respiratory depression.


Q: What happens if Curidol is taken for longer than the recommended treatment duration?

A: Regulatory documents state that risks like drug dependence, abuse, and severe withdrawal symptoms are generally known to increase with both higher doses and a longer duration of use.


Q: Does Curidol contain any common allergens like lactose, gluten, or certain dyes?

A: The inactive ingredients listed in the official labeling (excipients) for the tablets may contain substances such as lactose and specific coloring agents. Patients can review the full inactive ingredient list provided in the official product documents.


Q: Are there any special storage conditions required to maintain the effectiveness of Curidol?

A: Yes, official labeling requires the medicine to be stored at Controlled Room Temperature (typically 20 C to 25 C), protected from moisture, and kept securely out of sight and reach of children due to the risk of accidental overdose.


Q: What is the official classification of Curidol regarding its potential for misuse?

A: Due to the presence of Tramadol, the medicine is classified by regulatory bodies as a Controlled Substance. For example, in the United States, it is scheduled as a Schedule IV controlled substance.


Q: Does Curidol affect blood pressure or heart rate, if at all?

A: Official adverse reaction lists include reports of cardiovascular effects. Documented effects include orthostatic hypotension (a drop in blood pressure when standing) and changes in heart rhythm, such as palpitations.

How should Curidol be stored and disposed of?

Storage and Disposal of Curidol

Curidol (Acetaminophen and Tramadol Hydrochloride) must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and kept within a tight container.

Due to its Tramadol component, Curidol is a controlled substance and must be stored securely out of the sight and reach of children to prevent the risk of accidental fatal overdose.

For disposal, the FDA recommends utilizing drug take-back programs. If a program is unavailable, unused tablets should be removed from the container, mixed with an undesirable substance like coffee grounds, sealed in a bag, and then placed in the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Curidol found in:

A-Z Index: